主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
FHTX
#2701
Foghorn Therapeutics Inc. Common Stock
5.680
0
+0.89%
版块:
基础:
利润货币:
日范围
年范围
日变化
+0.89%
每月变动
-3.97%
6个月变化
+39.22%
年变化
+39.22%
前一天收盘价
5.630
0
Open
5.680
0
Bid
Ask
Low
5.680
0
High
5.680
0
交易量
33
市场
股票
医疗保健
FHTX
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
36.82 M
41.42 M
41.8 M
42.57 M
55.61 M
—
Valuation ratios
Enterprise value
653.48 M
846.18 M
219.51 M
194.21 M
207.04 M
729.79 M
Price to earnings ratio
—
-8.38
-2.48
-2.76
-2.99
-14.63
Price to sales ratio
—
644.51
14.06
7.93
11.46
44.83
Price to cash flow ratio
—
16.92
1.4
2.29
2.58
11.27
Price to book ratio
—
8.78
2 413.79
3.51
5.69
9.58
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.27
0.19
0.27
0.34
0.3
0.3
Return on equity %
0.47
1.05
972.32
1.27
1.9
1.14
Return on invested capital %
182.8
188.74
159.43
156.66
202.12
—
Gross margin %
100
100
100
100
100
400
Operating margin %
15.94 K
7 637.15
609.2
315.93
454.31
1 731.57
EBITDA margin %
—
—
—
—
—
—
Net margin %
16 K
7 680.06
566.36
288.1
383.15
1 429.78
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
10.12
9.44
6.37
4.11
3.73
11.67
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0.04
0.1
0.08
0.1
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.08
0
—
—
—
—
Long term debt to total equity ratio
0.13
0
—
—
—
—
Per share metrics
Operating cash flow per share
—
1.35
4.66
2.81
1.83
1.46
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
2.72
1.26
1.91
1.01
4.55
Net current asset value per share
—
12.36
8.45
5.72
4.55
14.29
Tangible book value per share
—
2.61
0
1.84
0.83
4.45
Working capital per share
—
11.05
7.12
4.33
3.33
9.35
Book value per share
—
2.61
0
1.84
0.83
4.45
新闻
Foghorn Therapeutics names Ryan Maynard as chief financial officer
Jefferies initiates Foghorn Therapeutics stock with buy rating
根据BTIG分析的今年顶级医疗保健股票
Top Healthcare Stocks for This Year According to BTIG
BTIG重申Foghorn Therapeutics为买入评级,将其列为2026年上半年首选股票
Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26
Stifel维持Foghorn Therapeutics股票买入评级,目标价12美元
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
BTIG 以买入评级开启对 Foghorn Therapeutics 的股票覆盖,看好其癌症管线
BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline
Foghorn Therapeutics任命Jeff Sacher为临时首席财务官和财务主管